In the current study, we made the notable discovery that the immune checkpoint CD80 was moderately expressed in FLT3-ITD AML cells, in contrast to its faint expression in wild-type FLT3 leukemic cells. This evidence concerns the gene CD80 and acute myeloid leukemia.